Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

Cited In for PubMed (Select 18056185)

1.

Curing myeloma at last: defining criteria and providing the evidence.

Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J.

Blood. 2014 Nov 13;124(20):3043-51. doi: 10.1182/blood-2014-07-552059. Epub 2014 Oct 7.

2.

The future of autologous stem cell transplantation in myeloma.

van Rhee F, Giralt S, Barlogie B.

Blood. 2014 Jul 17;124(3):328-33. doi: 10.1182/blood-2014-03-561985. Epub 2014 Jun 3. Review.

3.

Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.

van Laar R, Flinchum R, Brown N, Ramsey J, Riccitelli S, Heuck C, Barlogie B, Shaughnessy JD Jr.

BMC Med Genomics. 2014 May 17;7:25. doi: 10.1186/1755-8794-7-25.

4.

Complete response after autologous stem cell transplant in multiple myeloma.

Kumar L, Iqbal N, Mookerjee A, Verma RK, Sharma OD, Batra A, Pramanik R, Gupta R.

Cancer Med. 2014 Aug;3(4):939-46. doi: 10.1002/cam4.257. Epub 2014 Apr 29.

5.

Staging and prognostication of multiple myeloma.

Fonseca R, Monge J, Dimopoulos MA.

Expert Rev Hematol. 2014 Feb;7(1):21-31. doi: 10.1586/17474086.2014.882224. Review.

6.

Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma.

Bøgsted M, Bilgrau AE, Wardell CP, Bertsch U, Schmitz A, Bødker JS, Kjeldsen MK, Goldschmidt H, Morgan GJ, Dybkaer K, Johnsen HE.

PLoS One. 2013 Dec 20;8(12):e83252. doi: 10.1371/journal.pone.0083252. eCollection 2013.

7.

Association of response endpoints with survival outcomes in multiple myeloma.

Lonial S, Anderson KC.

Leukemia. 2014 Feb;28(2):258-68. doi: 10.1038/leu.2013.220. Epub 2013 Jul 19. Review.

8.

Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma.

Bergantim R, Trigo F, Guimarães JE.

Exp Hematol Oncol. 2012 Nov 26;1(1):35. doi: 10.1186/2162-3619-1-35.

9.

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B, AlSayed Y, Vanrhee F, Barlogie B.

Leukemia. 2013 Jan;27(1):226-32. doi: 10.1038/leu.2012.160. Epub 2012 Jun 18.

10.

Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.

Rajkumar SV.

Am J Hematol. 2012 Jan;87(1):78-88. doi: 10.1002/ajh.22237. Erratum in: Am J Hematol. 2012 Apr;87(4):452. Am J Hematol. 2014 Jun;89(6):669.

11.

Approach to the treatment of multiple myeloma: a clash of philosophies.

Rajkumar SV, Gahrton G, Bergsagel PL.

Blood. 2011 Sep 22;118(12):3205-11. doi: 10.1182/blood-2011-06-297853. Epub 2011 Jul 25.

12.

Treatment of multiple myeloma.

Rajkumar SV.

Nat Rev Clin Oncol. 2011 Apr 26;8(8):479-91. doi: 10.1038/nrclinonc.2011.63. Review.

13.

Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.

Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK, Bergsagel PL, Lacy MQ, Dingli DD, Ketterling RP, Buadi F, Kyle RA, Witzig TE, Greipp PR, Dispenzieri A, Kumar S.

Mayo Clin Proc. 2010 Jun;85(6):532-7. doi: 10.4065/mcp.2009.0677.

14.

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL.

Mayo Clin Proc. 2009 Dec;84(12):1095-110. doi: 10.4065/mcp.2009.0603.

15.

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.

Hoering A, Crowley J, Shaughnessy JD Jr, Hollmig K, Alsayed Y, Szymonifka J, Waheed S, Nair B, van Rhee F, Anaissie E, Barlogie B.

Blood. 2009 Aug 13;114(7):1299-305. doi: 10.1182/blood-2009-03-211953. Epub 2009 Jun 10.

16.

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, Crowley J, Barlogie B.

Blood. 2009 Sep 3;114(10):2068-76. doi: 10.1182/blood-2009-03-213280. Epub 2009 May 14.

17.

The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cells.

Guidicelli G, Chaigne-Delalande B, Dilhuydy MS, Pinson B, Mahfouf W, Pasquet JM, Mahon FX, Pourquier P, Moreau JF, Legembre P.

PLoS One. 2009;4(5):e5493. doi: 10.1371/journal.pone.0005493. Epub 2009 May 11.

18.

Treatment of myeloma: cure vs control.

Rajkumar SV.

Mayo Clin Proc. 2008 Oct;83(10):1142-5. doi: 10.4065/83.10.1142. Review. No abstract available.

19.

Multiple myeloma cancer stem cells.

Huff CA, Matsui W.

J Clin Oncol. 2008 Jun 10;26(17):2895-900. doi: 10.1200/JCO.2007.15.8428. Review.

20.

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.

Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, Alsayed Y, Waheed S, Petty N, Epstein J, Shaughnessy JD Jr, Tricot G, Zangari M, Zeldis J, Barer S, Crowley J.

Blood. 2008 Oct 15;112(8):3115-21. doi: 10.1182/blood-2008-03-145235. Epub 2008 May 20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk